In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates

Abstract

Rationale

[18F]Fallypride is a new and promising radiotracer, suitable for imaging D2 receptors with Positron Emission Tomography (PET) in both striatal and extrastriatal regions. The high signal to noise ratio of [18F]fallypride has been attributed to its high affinity for D2 receptors (K D of 0.03 nM, measured in vitro at room temperature).

Objectives

We sought to further characterize this tracer in terms of its in vivo affinity, possible affinity differences between brain regions and dependence of in vitro affinity on temperature.

Methods

PET scans were performed in baboons over a wide range of concentrations to measure the in vivo K D of [18F]fallypride in striatal and extrastriatal regions. Several analytical approaches were used, including nonlinear kinetic modeling and equilibrium methods. Also, in vitro assays were performed at 22 and 37°C.

Results

No significant differences in the in vivo K D were detected between regions. In vivo K D of [18F]fallypride was 0.22±0.05 nM in striatum, 0.17±0.05 nM in thalamus, and 0.21±0.07 nM in hippocampus. These values were intermediate between in vitro K D measured at 22 (0.04±0.03 nM) and 37 degrees (2.03±1.07 nM).

Conclusion

The in vivo affinity of [18F]fallypride was not as high as previously estimated from in vitro values. This property might contribute to the favorable kinetic properties of the tracer. The in vivo affinity was similar between striatal and extrastriatal regions. This result indicates that the measured regional in vivo affinities of this tracer are not affected by putative regional differences in endogenous dopamine, and that [18F]fallypride is an appropriate tool to provide unbiased estimates of the occupancy of D2 receptors by antipsychotic drugs in striatal and extrastriatal regions.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Abi-Dargham A, Laruelle M, Seibyl J, Rattner Z, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Bremner JD, Hyde TM, Charney DS, Hoffer PB, Innis RB (1994) SPECT measurement of benzodiazepine receptors in human brain with [123-I]iomazenil: kinetic and equilibrium paradigms. J Nucl Med 35:228–238

    CAS  PubMed  Google Scholar 

  2. Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang DR, Anjilvel S, Zea-Ponce Y, Lombardo I, Van Heertum R, Mann JJ, Foged C, Halldin C, Laruelle M (1999) PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 32:93–109

    CAS  PubMed  Google Scholar 

  3. Abi-Dargham A, Hwang DR, Huang Y, Zea-Ponce Y, Martinez D, Lombardo I, Broft A, Hashimoto T, Slifstein M, Mawlawi O, Van Heertum R, Laruelle M (2000) Reliable quantification of both striatal and extrastriatal D2 receptors in humans with [18F]fallypride. J Nucl Med 41:139P

    Google Scholar 

  4. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS (2000) Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 150:132–140

  5. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23:5–14

    Article  CAS  PubMed  Google Scholar 

  6. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H, Haberkorn U, Doll J, Oberdorfer F, Lorenz WJ (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. National electrical manufacturers association. J Nucl Med 38:1614–1623

    CAS  PubMed  Google Scholar 

  7. Carson RE (1986) Parameters estimation in positron emission tomography. In: Phelps ME, Mazziotta JC, Schelbert HR (eds) Positron emission tomography. Principles and applications for the brain and the heart. Raven, New York, pp 347–390

  8. Christian BT, Narayanan TK, Shi B, Mukherjee J (2000) Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [(18)F]fallypride in nonhuman primates. Synapse 38:71–79

    Article  CAS  PubMed  Google Scholar 

  9. Delforge J, Bottlaender M, Loc’h C, Guenther I, Fuseau C, Bendriem B, Syrota A, Maziere B (1999) Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach. J Cereb Blood Flow Metab 19:533–546

    Article  CAS  PubMed  Google Scholar 

  10. Delforge J, Bottlaender M, Pappata S, Loc’h C, Syrota A (2001) Absolute quantification by positron emission tomography of the endogenous ligand. J Cereb Blood Flow Metab 21:613–630

    Article  CAS  PubMed  Google Scholar 

  11. Ehrin E, Farde L, de Paulis T, Eriksson L, Greitz T, Johnstrom P, Litton JE, Nilsson JL, Sedvall G, Stone-Elander S (1985) Preparation of 11C-labelled raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey. Int J Appl Radiat Isot 36:269–273

    Article  CAS  PubMed  Google Scholar 

  12. Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedstrom CG, Litton JE, Sedvall G (1985) Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 82:3863–3867

    CAS  PubMed  Google Scholar 

  13. Farde L, Hall H, Ehrin E, Sedvall G (1986) Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 231:258–261

    CAS  PubMed  Google Scholar 

  14. Farde L, Eriksson L, Blomquist G, Halldin C (1989) Kinetic analysis of central [11C]raclopride binding to D2 dopamine receptors studied by PET—a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 9:696–708

    CAS  PubMed  Google Scholar 

  15. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C (1997) A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133:396–404

    CAS  PubMed  Google Scholar 

  16. Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, Burger C, Staley JK, Rajeevan N, Charney DS, Innis RB (1999) Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. Synapse 34:290–304

    Article  CAS  PubMed  Google Scholar 

  17. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB (1994) Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers: β-CIT, IBF and iomazenil. J Pharmaceutical Sci 83:1014–1019

    CAS  Google Scholar 

  18. Hall H, Wedel I, Halldin C, J K, Farde L (1990) Comparison of the in vitro binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. J Neurochem 55:2048–2057

    CAS  PubMed  Google Scholar 

  19. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245–256

    Google Scholar 

  20. Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T, Karlsson P, Nakashima Y, Swahn CG (1995) Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36:1275–1281

    CAS  PubMed  Google Scholar 

  21. Kessler RM, Mason NS, Votaw JR, De Paulis T, Clanton JA, Ansari MS, Schmidt DE, Manning RG, Bell RL (1992) Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 223:105–107

    CAS  PubMed  Google Scholar 

  22. Kohler C, Hall H, Ogren SO, Gawell L (1985) Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochemical Pharmacology 34:2251–2259

    Article  CAS  PubMed  Google Scholar 

  23. Kornhuber J, Brücke T, Angelberger P, Asenbaum S, Podreka I (1995) SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect 101:95–103

    CAS  PubMed  Google Scholar 

  24. Kung HF, Kasliwal R, Pan S, Kung M-P, Mach RH, Guo Y-Z (1988) Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of R-(+)- and S-(−)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide. J Med Chem 31:1039–1043

    CAS  PubMed  Google Scholar 

  25. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451

    CAS  PubMed  Google Scholar 

  26. Laruelle M, Abi-Dargham A, Al-Tikriti MS, Baldwin RM, Zea-Ponce Y, Zoghbi SS, Charney DS, Hoffer PB, Innis RB (1994a) SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14:453–465

    CAS  PubMed  Google Scholar 

  27. Laruelle M, Al-Tikriti MS, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB (1994b) In vivo quantification of dopamine D2 receptors parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol 263:39–51

    Article  CAS  PubMed  Google Scholar 

  28. Laruelle M, Iyer RN, Al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB, Bradberry CW (1997) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1–14

    PubMed  Google Scholar 

  29. Laruelle M, Slifstein M, Huang Y (2003) Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 5:363–375

    Article  PubMed  Google Scholar 

  30. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834–840

    CAS  PubMed  Google Scholar 

  31. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217–227

    CAS  PubMed  Google Scholar 

  32. Moghaddam B, Berridge CW, Goldman-Rakic PS, Bunney BS, Roth RH (1993) In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 13:215–222

    CAS  PubMed  Google Scholar 

  33. Mukherjee J, Yang ZY, Das MK, Brown T (1995a) Fluorinated benzamide neuroleptics. III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22:283–296

    Article  CAS  PubMed  Google Scholar 

  34. Mukherjee J, Yang ZY, Das MK, Brown T (1995b) Fluorinated benzamide neuroleptics. III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22:283–296

    Article  CAS  PubMed  Google Scholar 

  35. Mukherjee J, Yang ZY, Lew R, Brown T, Kronmal S, Cooper MD, Seiden LS (1997) Evaluation of d-amphetamine effects on the binding of dopamine D-2 receptor radioligand, F-18-fallypride in nonhuman primates using positron emission tomography. Synapse 27:1–13

    CAS  PubMed  Google Scholar 

  36. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X, Yasillo N, Chen CT, Mintzer R, Cooper M (1999) Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 26:519–527

    Article  CAS  PubMed  Google Scholar 

  37. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J (2000) Measurement of striatal and extrastriatal D-2 receptor occupancy by clozapine and risperidone unsing [18F]fallypride and PET. Neuroimage 11:S53

    Article  Google Scholar 

  38. Mukherjee J, Christian BT, Narayanan TK, Shi B, Mantil J (2001) Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25:476–488

    Article  CAS  PubMed  Google Scholar 

  39. Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M, Mantil J (2002) Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46:170–188

    Article  CAS  PubMed  Google Scholar 

  40. Narendran R, Talbot PS, Slifstein M, Sudo Y, Guo N, Hackett E, Ali M, Huang Y, Hwang DR, Laruelle M (2002) Effects of d-amphetamine on the binding of [18F]fallypride in striatal and extrastriatal regions in baboons: single bolus and bolus plus constant infusion studies. J Nucl Med 43:106P

    Google Scholar 

  41. Olsson H, Halldin C, Swahn CG, Farde L (1999) Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 19:1164–1173

    CAS  PubMed  Google Scholar 

  42. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490–491

    CAS  Google Scholar 

  43. Price JC, Mayberg HS, Dannals RF, Wilson AA, Ravert HT, Sadzot B, Rattner Z, Kimball A, Feldman MA, Frost JJ (1993) Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and [11C]-flumazenil. J Cereb Blood Flow Metab 13:656–667

    CAS  PubMed  Google Scholar 

  44. Rieck RW, Ansari MS, Whetsell WO, Deutch AY, Kessler RM (2003) Distribution of dopamine D(2)-like receptors in the human thalamus: autoradiographic and PET studies. Neuropsychopharmacology

  45. Rowland M, Tozer TN (1989) Clinical pharmacokinetics, 2nd edn. Lea & Febiger, Philadelphia, PA

  46. Sadzot B, Price JC, Mayberg HS, Douglass KH, Dannals RF, Lever JR, Ravert HT, Wilson AA, Wagner HN Jr, Feldman MA, Frost JJ (1991) Quantification of human opiate receptor concentration and affinity using high and low specific activity [11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 11:204–219

    CAS  PubMed  Google Scholar 

  47. Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660–672

    CAS  Google Scholar 

  48. Seeman P, Guan H-C, Niznik HB (1989) Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3:96–97

    CAS  PubMed  Google Scholar 

  49. Slifstein M, Laruelle M (2001) Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl Med Biol 28:595–608

    Article  CAS  PubMed  Google Scholar 

  50. Stephenson C, Bigliani V, Jones H, Mulligan R, Acton P, Visvikis D, Ell P, Kerwin R, Pilowsky L (2000) Striatal and extra-striatal D2/D3 dopamine receptor occupancy by quetiapine in vivo. Br J Psychiatry 177:408–415

    CAS  PubMed  Google Scholar 

  51. Suhara T, Sudo Y, Okauchi T, Maeda J, Kawabe K, Suzuki K, Okubo Y, Nakashima Y, Ito H, Tanada S, Halldin C, Farde L (1999) Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. Int J Neuropsychopharmcol 2:73–82

    Article  CAS  PubMed  Google Scholar 

  52. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001) No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 158:926–930

    CAS  PubMed  Google Scholar 

  53. Woods RP, Mazziotta JC, Cherry SR (1993) MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17:536–546

    CAS  PubMed  Google Scholar 

  54. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B, Paillere-Martinot ML (2001a) Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503–508

    Article  CAS  PubMed  Google Scholar 

  55. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc’h C, Maziere B, Paillere-Martinot ML (2001b) In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21:207–214

    Article  CAS  PubMed  Google Scholar 

  56. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T, Tanada S (2001) Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl) 154:112–114

Download references

Acknowledgements

The authors would like to thank Samir Abdelhadi, Mohammed Ali, Elizabeth Hackett, Kimchung Ngo, Van Phan, and Lyudmilla Savenkova for excellent technical assistance. Supported by the National Alliance for Research in Schizophrenia and Depression (NARSAD), the Lieber Center for Schizophrenia Research at Columbia University and the Public Health Service (NIMH K02 MH01603-0, NIMH MH59342-01, NIAAA IP50 AA-1287001).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Mark Slifstein.

Appendix A

Appendix A

Simulations were performed to test the combined effects of three error sources on K D estimation using the TAC method, where ROI–CER is used as an estimate of bound concentration: (1) differences in kinetics between CER and C 2, (2) failure to accurately capture the peak specific binding due to discrete sampling and (3) differences in nonspecific binding between CER and ROIs. Simulated CER and ROI were constructed according to Eq. 2 and the system given by Eqs. 15, 16, respectively. All parameters were obtained from the experimental data as the average over the tracer dose experiments. Plasma curves were formed as a line segment from 0 to peak value during time t=0 to 1.5 min and a sum of three decaying exponentials from t=1.5 to 200 min. Kinetic parameters for CER and ROI were [K1, k2]=[0.37, 0.19] and [K 1, k 2, k 3, k 4, k +]=[0.56, 0.56/V 2, B max×k +, 0.03, 0.03×f 2/K D], respectively. K D was fixed at 0.2 nM; f 2 was computed as f 1×V 2 with f 1 fixed at 0.28. Three levels of nonspecific binding differences were used. V 2 was set to 0.9, 1 and 1.1 times K1/k2, corresponding to the range seen in the blocking experiments. At each level of V 2, B max ranged from 2.5 to 24 nM. For each B max and V 2 pair, six curves were formed with plasma magnitudes in proportion to the six injected masses from the real data. Simulated PET data were then formed by sampling these curves at the midframe times of the PET protocol. Scatchard plots were formed using ROI–CER to estimate peak bound and CER to estimate free plus nonspecifically bound concentration at the time of peak bound. The results are shown in Fig. 6. Estimated K D is plotted against B max for each level of V 2, yielding three curves. For B max≤5, K D is overestimated at all levels of V 2, with the overestimation higher at V 2=1.1 × CER distribution volume (similar to V 2 of hippocampus in blocking studies) than at V 2=0.9 × CER distribution volume (similar to V 2 of thalamus in blocking studies). For B max≥20 nM (similar to striatum), K D estimates are close to true K D at all levels of V 2.

Fig. 6
figure6

Results from simulations of combined effects of differences in CER and C 2 kinetics, discrete sampling and regional nonspecific binding differences when ROI–CER is used as an approximation to bound concentration (TAC method). Horizontal lines are drawn at K D=0.15, 0.20 and 0.25 nM. True K D was set at 0.20 nM in the simulations

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Slifstein, M., Hwang, DR., Huang, Y. et al. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology 175, 274–286 (2004). https://doi.org/10.1007/s00213-004-1830-x

Download citation

Keywords

  • Positron emission tomography
  • [18F]Fallypride
  • D2 receptor imaging